These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34904690)

  • 1. Serum Cytokeratin 18 as a Metastatic and Therapeutic Marker for Extramammary Paget's Disease.
    Urano-Takaoka M; Sumida H; Miyagawa T; Awaji K; Nagai K; Omatsu J; Miyake T; Sato S
    Acta Derm Venereol; 2022 Jan; 102():adv00636. PubMed ID: 34904690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease.
    Nakamura Y; Tanese K; Hirai I; Amagai M; Kawakami Y; Funakoshi T
    Br J Dermatol; 2019 Sep; 181(3):535-543. PubMed ID: 30791097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum cytokeratin 19 fragment 21-1 is a useful tumor marker for the assessment of extramammary Paget's disease.
    Kato J; Sumikawa Y; Hida T; Kamiya T; Horimoto K; Kamiya S; Sato S; Takahashi H; Sawada M; Yamashita T
    J Dermatol; 2017 Jun; 44(6):666-670. PubMed ID: 28150330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified weekly regimen of cisplatin, epirubicin and paclitaxel induced a durable response in two cases of metastatic extramammary Paget's disease.
    Hirai I; Funakoshi T
    J Dermatol; 2017 Oct; 44(10):1148-1151. PubMed ID: 28406527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of lymph node dissection in the treatment of extramammary Paget's disease: A single-institution study.
    Tsutsui K; Takahashi A; Muto Y; Mizuta H; Jinnai S; Nakama K; Ogata D; Namikawa K; Yamazaki N
    J Dermatol; 2020 May; 47(5):512-517. PubMed ID: 32157716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Factors of Extramammary Paget's Disease.
    Hatta N
    Curr Treat Options Oncol; 2018 Aug; 19(10):47. PubMed ID: 30112691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease.
    Gatalica Z; Vranic S; Krušlin B; Poorman K; Stafford P; Kacerovska D; Senarathne W; Florento E; Contreras E; Leary A; Choi A; In GK
    Cancer Med; 2020 Feb; 9(4):1441-1450. PubMed ID: 31899853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy may be more appropriate for ERBB2 low-expressing extramammary paget's disease patients: a prognosis analysis and exploration of targeted therapy and immunotherapy of extramammary paget's disease patients.
    Yang J; Chen Y; Zhang X; Tong Z; Weng S; Zhu N; Yuan Y
    Cancer Immunol Immunother; 2024 Oct; 73(12):252. PubMed ID: 39358617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel ex vivo disease model for extramammary Paget's disease using the cancer tissue-originated spheroid method.
    Arita T; Kondo J; Kaneko Y; Tsutsumi M; Kanemaru M; Matsui M; Arakawa Y; Katoh N; Inoue M; Asai J
    J Dermatol Sci; 2020 Sep; 99(3):185-192. PubMed ID: 32800410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pathological characteristics of extramammary Paget's disease: report of 246 Chinese male patients.
    Kang Z; Zhang Q; Zhang Q; Li X; Hu T; Xu X; Wu Z; Zhang X; Wang H; Xu J; Xu F; Guan M
    Int J Clin Exp Pathol; 2015; 8(10):13233-40. PubMed ID: 26722523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum cell-free DNA levels are a useful marker for extramammary Paget disease.
    Mijiddorj T; Kajihara I; Tasaki Y; Otsuka-Maeda S; Sakamoto R; Sawamura S; Kanazawa-Yamada S; Egashira S; Inoue K; Makino K; Miyashita A; Aoi J; Igata T; Makino T; Masuguchi S; Fukushima S; Jinnin M; Morinaga J; Ikeda T; Ihn H
    Br J Dermatol; 2019 Sep; 181(3):505-511. PubMed ID: 30706452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of laminin-5 gamma 2 chain predicts invasion of extramammary Paget's disease cell.
    Tohmatsu Y; Imura J; Sakai T; Takagi K; Minamisaka T; Tanaka S; Noguchi A; Nakajima T; Nagata T; Makino T; Shimizu T; Fujii T
    APMIS; 2021 Jan; 129(1):3-8. PubMed ID: 32996218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of Janus kinase 2 protein in extramammary Paget's disease.
    Otsuka-Maeda S; Mijiddorj MT; Kajihara I; Sakamoto R; Yamada-Kanazawa S; Kanemaru H; Nishimura Y; Sawamura S; Makino K; Aoi J; Makino T; Masuguchi S; Fukushima S; Ihn H
    Jpn J Clin Oncol; 2021 Jul; 51(7):1176-1178. PubMed ID: 33912910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined serum carcinoembryonic antigen and cytokeratin 19 fragment levels provide a sensitive biomarker for lymph node metastasis in extramammary Paget's disease.
    Kato H; Nakamura M; Watanabe S; Oda T; Morita A
    J Dermatol; 2020 Jul; 47(7):763-769. PubMed ID: 32415799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of metastatic extramammary Paget's disease that responded to combination chemotherapy.
    Yamazaki N; Yamamoto A; Wada T; Ishikawa M; Moriya Y; Nakanishi Y
    J Dermatol; 1999 May; 26(5):311-6. PubMed ID: 10380432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trop2 Expression in Extramammary Paget's Disease and Normal Skin.
    Ito T; Tanegashima K; Tanaka Y; Hashimoto H; Murata M; Oda Y; Kaku-Ito Y
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of low-dose 5-fluorouracil/cisplatin therapy for invasive extramammary Paget's disease.
    Kato H; Watanabe S; Kariya K; Nakamura M; Morita A
    J Dermatol; 2018 May; 45(5):560-563. PubMed ID: 29446148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of HER-2 in extramammary Paget's disease.
    Masuguchi S; Jinnin M; Fukushima S; Makino T; Sakai K; Inoue Y; Igata T; Ihn H
    Biosci Trends; 2011 Aug; 5(4):151-5. PubMed ID: 21914949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-155, a potential serum marker of extramammary Paget's disease.
    Guo H; Qi RQ; Sheng J; Liu C; Ma H; Wang HX; Li JH; Gao XH; Wan YS; Chen HD
    BMC Cancer; 2018 Nov; 18(1):1078. PubMed ID: 30458743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NECTIN4-targeted antibody-drug conjugate is a potential therapeutic option for extramammary Paget disease.
    Tanaka Y; Ito T; Murata M; Tanegashima K; Kaku-Ito Y; Nakahara T
    Exp Dermatol; 2024 Mar; 33(3):e15049. PubMed ID: 38509717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.